A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
Stopped Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
Conditions
- Respiratory Syncytial Virus
Interventions
- DRUG: Rilematovir
- DRUG: Placebo
Sponsor
Janssen Research & Development, LLC